Samuel Strober
American physician
From Wikipedia, the free encyclopedia
Samuel Strober (May 8, 1940-February 11, 2022 (aged 81)[1]) was a biomedical researcher and inventor best known for his work on the elimination of the need for lifelong immune suppressive drugs in organ transplant patients.[2]
Samuel Strober | |
|---|---|
| Died | February 11, 2022 |
| Education | Columbia College Harvard Medical School |
| Occupation | Physician |
| Spouse |
|
| Medical career | |
| Institutions | Stanford Medical School |
Strober was born in Brooklyn, New York, on May 8, 1940, and received his bachelor's degree from Columbia College in 1961,[1][3] and his MD from the Harvard Medical School[4] in 1966. He also studied at Massachusetts General[5] and Stanford University Hospitals[6] and the Sir William Dunn School of Pathology[7] at Oxford University.
He was chief of the Division of Immunology and Rheumatology[8][9] at the Stanford University School of Medicine (1979–1997); a co-founder of a biotechnology company, Dendreon, that developed the first FDA approved cancer vaccination; President of the Clinical Immunology Society (1996);[10] and chairman of the Board of Directors of the La Jolla Institute for Allergy and Immunology.[11][12][13] He also co-founded Medeor Therapeutics.[14]
Personal life
His first wife is feminist economist Myra Strober, who decided to keep the Strober last name after she remarried.[15][16]